Cancer drug trial brings mixed result

A LONG-awaited trial has found a new drug does not improve overall survival rates in breast cancer patients.

But the study involving 3,300 patients found zoledronic acid did lead to a major 29 per cent improvement in survival among post-menopausal women.

Prof Rob Coleman, of Sheffield University, who headed the trial, said: "In the larger population, we did not see a difference but in the post-menopausal women a survival advantage like this is quite remarkable and the difference in outcome between this group and the younger population is unlikely to be a chance finding."

Experts from Leeds University last week reported zoledronic acid, which is used in bone health, improved survival by six months in patients with multiple myeloma.

Back to the top of the page